Common questions about Rekovelle (FAQ)
Q: What is the main difference between Rekovelle and other fertility injections like Gonal-f or Follistim?
Official product information describes Rekovelle as different from other fertility injections primarily due to its active substance, follitropin delta, which is produced in a human cell line. This unique manufacturing process results in a distinct glycosylation profile, a feature supported by pharmacological studies. Additionally, unlike conventional products that use International Units, the personalized dosing is calculated based on a woman's AMH concentration and body weight.
Q: Why is the Rekovelle dose determined by AMH level and body weight?
The official dosing method is designed to be personalized to each woman. By using both the Anti-Müllerian Hormone (AMH) level and body weight to determine the initial dose, the overall goal is to facilitate an appropriate ovarian response and support risk mitigation related to Ovarian Hyperstimulation Syndrome (OHSS).
Q: Is there a known risk of ovarian tumors associated with long-term Rekovelle use?
Official safety data indicates that it has not been established whether or not treatment with fertility medicines known as gonadotropins increases the risk of ovarian and other reproductive system neoplasms (tumours) in women with infertility. Treatment protocols require that potential pre-existing conditions and risks be evaluated before initiation.
Q: Can Rekovelle be used by women who have Polycystic Ovarian Syndrome (PCOS)?
The official contraindication against using this medicine is limited to ovarian enlargement or ovarian cysts that are NOT due to Polycystic Ovarian Syndrome (PCOS). However, official documents indicate that patients with PCOS may have an increased risk of developing Ovarian Hyperstimulation Syndrome (OHSS), necessitating close medical oversight.
Q: Why is a specific cell line (PER.C6) used to produce the active substance in Rekovelle?
Follitropin delta, the active substance, is the first recombinant FSH produced in a human cell line (PER.C6) using recombinant DNA technology. This origin results in a distinct glycosylation profile (a specific pattern of sugar molecules attached to the protein). This profile is thought to be relevant to the drug's activity and its elimination kinetics from the body.
Q: What level of Anti-Müllerian Hormone (AMH) is generally considered appropriate for starting Rekovelle?
The level of Anti-Müllerian Hormone (AMH) is used to calculate the individualized starting dose, not for overall eligibility. Official product information notes a specific threshold: for women with an AMH concentration below 15 pmol/L, the fixed daily dose used in clinical practice is 12 micrograms.
Q: Is the pain or discomfort in the pelvic area a common sign of a serious side effect?
Pelvic discomfort or pain is commonly reported in official safety documents. A worsening of pain—especially when combined with symptoms like nausea, vomiting, diarrhoea, or significant swelling—is a sign that Ovarian Hyperstimulation Syndrome (OHSS) may be developing and requires medical attention.
Q: Can women who have a history of blood clots use Rekovelle?
Official prescribing information indicates that women with a recent or ongoing history of thromboembolic disease (blood clots) or recognized risk factors, such as being significantly overweight ( BMI > 30 kg/m^2), may have an increased risk during or following treatment. The decision to initiate treatment requires a medical assessment where the potential benefits are weighed against these known risks.
Q: Why do official documents mention unexplained vaginal bleeding as a reason not to use Rekovelle?
Gynaecological haemorrhage (vaginal bleeding) of unknown cause is listed as a contraindication in official documents. This is because before treatment, it is important to rule out underlying serious conditions, such as cancers of the reproductive system, which are also conditions for which the medicine must not be used.
Q: What is the recommended injection site for Rekovelle, and why?
The medicine is administered as a subcutaneous injection, which means under the skin, and is preferably given in the abdominal wall. This site is listed as the preferred area for subcutaneous administration.
Q: Why must the first injection of Rekovelle be done under medical supervision?
Official regulatory documents state that the very first injection must be performed under direct medical supervision. This is primarily so that patients can be educated on how to use the pre-filled injection pen correctly and safely, and to ensure the proper administration technique is taught and understood.
Q: What is the glycosylation difference between Rekovelle (follitropin delta) and follitropin alfa?
Follitropin delta is distinct due to its unique glycosylation profile. This refers to the pattern of sugar molecules attached to the protein. Follitropin delta is characterized by containing both 2,3- and 2,6-linked sialic acids, which is different from other recombinant FSH products.
Q: What is the meaning of subcutaneous use when referring to the injection?
Subcutaneous use simply means that the medicine is administered as an injection that goes under the skin, into the fatty layer. This is the intended route of administration for the Rekovelle pre-filled pen.
Q: How is the overall risk/benefit ratio for Rekovelle viewed by medical bodies?
The European Medicines Agency (EMA) and its Committee for Medicinal Products for Human Use (CHMP) concluded that the medicine's benefits are greater than its risks. This view supported its approval for use in Controlled Ovarian Stimulation (COS), with the overall safety profile considered acceptable and similar to the established comparator treatment.
Q: What makes Rekovelle a personalized dosing treatment compared to conventional FSH?
Rekovelle is considered personalized because, unlike conventional FSH, the starting dose is not based on a standard unit but is calculated using a woman's individual serum Anti-Müllerian Hormone (AMH) concentration and body weight. This method is designed to optimize the ovarian response specifically for that individual.
Q: What are the specific symptoms of a severe allergic reaction to Rekovelle?
Although allergic reactions are rare, signs of a severe allergic reaction include swelling of the face, lips, tongue, or other body parts, and these events require emergency medical care. Other symptoms described in official patient information are shortness of breath, wheezing, difficulty breathing, rash, itching, or hives on the skin.
Q: What are the specific ingredients (non-medicinal) contained in Rekovelle?
The non-medicinal ingredients, or excipients, in the solution are phenol, polysorbate 20, L-methionine, sodium sulphate decahydrate, disodium phosphate dodecahydrate, concentrated phosphoric acid, sodium hydroxide, and water for injections.
Q: How does Rekovelle compare to other FSH drugs in terms of half-life in the body?
Official pharmacokinetic data indicates that the terminal elimination half-life is approximately 40 hours after a single injection, and about 28 hours after repeated daily injections.
Q: Is there a higher risk of ectopic pregnancy associated with using Rekovelle for IVF?
Official regulatory documents indicate that the prevalence of ectopic pregnancy (a pregnancy outside the uterus) after Assisted Reproductive Technology (ART) procedures, such as IVF, has been reported to be higher than in the general population. This risk is generally associated with underlying fertility issues and the Assisted Reproductive Technology (ART) procedure itself.
Q: Does Rekovelle increase the general risk of birth defects?
Studies and official information state that the prevalence of congenital malformation (birth defects) is reported to be slightly higher after ART than after spontaneous conceptions. This is often attributed to patient factors (like maternal age, genetics) or the ART procedures themselves. An effect specifically due to the medicine has not been ruled out in regulatory documents.
Q: What are the indications of Ovarian Hyperstimulation Syndrome (OHSS) I should look out for?
Ovarian Hyperstimulation Syndrome (OHSS) is a potentially serious side effect. Official safety documents list key symptoms to watch for, including abdominal pain, discomfort or swelling (bloating), nausea, vomiting, diarrhoea, weight gain, and sometimes difficulty breathing or decreased urination. These symptoms are signs that the condition may be worsening and require immediate medical care.
Q: Can Rekovelle affect the ability to drive or operate machinery?
Official product information, according to the regulatory assessment, states that Rekovelle has no or negligible influence on a person's ability to drive vehicles and use machines.
Q: Is it safe to use Rekovelle if I have a history of thyroid problems?
Official prescribing information advises that patients should be evaluated for certain conditions, including hypothyroidism (underactive thyroid), and treated appropriately for those conditions before starting treatment with Rekovelle.
Q: Does Rekovelle increase the risk of getting fibroids?
The medicine must not be used in women who have fibroid tumours of the uterus that are considered incompatible with pregnancy. It is not established in official documents whether or not treatment with gonadotropins increases the risk of developing these tumours.
Q: What should be done if the injection solution appears cloudy or contains particles?
Official regulatory information specifies that the solution must be checked visually before injection. The medicine should not be administered if the solution contains particles or is not clear (for example, if it appears cloudy). The solution must be clear and colorless.
Q: How is the dose of Rekovelle rounded off using the injection pen's scale?
The individualized dose must be set accurately on the injection pen. Official instructions state that the calculated dose is to be rounded off to the nearest 0.33 micrograms to align precisely with the dosing scale available on the injection pen.
Q: Does Rekovelle contain sodium?
Yes, regulatory documents listing the excipients (non-medicinal ingredients) show that the injection solution contains substances with sodium, specifically sodium sulphate decahydrate and sodium hydroxide.
Q: Can the active substance in Rekovelle, follitropin delta, be measured in the blood after injection?
Yes, official pharmacokinetic data indicates that the active substance, follitropin delta, is measurable in the blood after injection. After daily subcutaneous administration, the time to reach the maximum serum concentration (the highest level in the blood) is approximately 10 hours.
Q: What is the risk of pregnancy loss following fertility treatments like those using Rekovelle?
Official regulatory documents indicate that the incidence of pregnancy loss by miscarriage or abortion is known to be higher in patients undergoing controlled ovarian stimulation for ART compared to following natural conception. This risk is associated with the underlying factors of infertility and the ART process.
Q: Are there different strengths of the Rekovelle pre-filled pen available?
Yes, according to official regulatory data, Rekovelle is available in pre-filled pens containing different total amounts of the active ingredient, such as 12 micrograms, 36 micrograms, and 72 micrograms presentations.
Q: Is there any restriction on the use of Rekovelle for patients with a high BMI (obesity)?
While there is no blanket restriction on use based on BMI alone, official safety documents note that women who are overweight ( BMI > 30 kg/m^2) and undergoing ART treatment have an increased risk of blood clots (thromboembolic events). This risk factor is part of the overall medical assessment during treatment planning.
